Liquidia vs Pharming
LQDA and PHAR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LQDA and PHAR compare
Liquidia grew revenue faster over the last twelve months (798% versus 26.6% for Pharming).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −15.1% at Liquidia.
Liquidia scores higher on the StockData Score (10 against 8 for Pharming), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LQDA | PHAR |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | – |
| Share price | $57.41 | $12.60 |
| Change, 1 year | 103% | −26.5% |
| Change, 5 years | 1248% | 46.2% |
| Beta (5Y) | 0.97 | 0.55 |
| Employees | 216 | 50K |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.3× | – |
| P/FCF | 17.6× | – |
| FCF yield | 5.7% | – |
| Growth | ||
| Revenue growth (TTM) | 798% (better) | 26.6% |
| Revenue growth, 5Y average | 192% (better) | 12.1% |
| EPS growth, 5Y average | – | −40.8% |
| Profitability | ||
| Gross margin | – | 87.9% |
| Operating margin | −15.6% | 6.9% (better) |
| Net margin | −15.1% | 0.76% (better) |
| FCF margin | 46.8% (better) | 14.3% |
| Financial health | ||
| Interest coverage | – | 132× |
| Current ratio | 1.02 | 2.59 (better) |
| Altman Z-score | 3.31 | – |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 81.1% | 0.32% |
| Held by insiders | 19.5% | 0.00% |
| Insider net buying, 12 months | −$227M | – |
| Short interest, % of float | 24.3% | – |
Go deeper
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.